The Role of the E3 Ligase Cbl-B in Murine Dendritic Cells

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Wallner, Stephanie ^a,b   Lutz Nicoladoni, Christina ^a,b   Tripp, Christoph H ^c   Gastl, Günther ^a,b   Baier, Gottfried ^c   Penninger, Josef M ^d   Stoitzner, Patrizia ^c   Wolf, Dominik ^a,e  

^a TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^b Internal Medicine V   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^e UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CBL B PROTEIN; CBL PROTEIN; CD205 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; LIPOPOLYSACCHARIDE; LYMPHOCYTE ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; OVALBUMIN; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; CBLB PROTEIN, MOUSE; CELL SURFACE RECEPTOR; CYTOKINE; DEC-205 RECEPTOR; DEXTRAN; FLUORESCEIN ISOTHIOCYANATE; LECTIN; LEUKOCYTE ANTIGEN; PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LYMPH NODE; MELANOMA; MELANOMA B16; MIXED LYMPHOCYTE REACTION; MONONUCLEAR CELL; MOUSE; NONHUMAN; PINOCYTOSIS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SURVIVAL RATE; TUMOR VOLUME; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; BONE MARROW CELL; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MELANOMA, EXPERIMENTAL; METABOLISM; MIXED LYMPHOCYTE CULTURE; PATHOLOGY; SKIN NEOPLASMS; TRANSPORT AT THE CELLULAR LEVEL;

MURINAE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, CD; BIOLOGICAL TRANSPORT; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CYTOKINES; DENDRITIC CELLS; DEXTRANS; FLUORESCEIN-5-ISOTHIOCYANATE; GENE EXPRESSION; LECTINS, C-TYPE; LIPOPOLYSACCHARIDES; LYMPHOCYTE CULTURE TEST, MIXED; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; OVALBUMIN; PEPTIDES; POLY I-C; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTORS, CELL SURFACE; SKIN NEOPLASMS; UBIQUITIN-PROTEIN LIGASES;

EID: 84878783226     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065178     Document Type: Article

References (57)

1. Steinman RM, (2012) Decisions about dendritic cells: past, present, and future. Annual Review of Immunology 30: 1-22.
2. Den Brok MHMGM, Nierkens S, Figdor CG, Ruers TJM, Adema GJ, (2005) Dendritic cells: tools and targets for antitumor vaccination. Expert Review of Vaccines 4: 699-710.
3. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, et al. (1998) Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. The Prostate 36: 39-44.
4. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM, (2009) Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunology, Immunotherapy 58: 1-14.
5. Delamarre L, Mellman I, (2011) Harnessing dendritic cells for immunotherapy. Seminars in Immunology 23: 2-11.
6. Schuler G, (2010) Dendritic cells in cancer immunotherapy. European Journal of Immunology 40: 2123-2130.
7. Nau MM, Lipkowitz S, (2003) Comparative genomic organization of the cbl genes. Gene 308: 103-113.
8. Wallner S, Gruber T, Baier G, Wolf D, (2012) Targeting Cbl-b to enhance lymphocyte effector function. Developmental and Clinical Immunology 2012: 1-5.
9. Chiou S-H, Shahi P, Wagner RT, Hu H, Lapteva N, et al. (2011) The E3 ligase c-Cbl regulates dendritic cell activation. EMBO reports: 1-9.
10. Han C, Jin J, Xu S, Liu H, Li N, et al. (2010) Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nature Immunology 11: 734-742.
11. Kaisho T, Akira S, (2002) Toll-like receptors as adjuvant receptors. Biochimica et Biophysica Acta 1589: 1-13.
12. Takeda K, Kaisho T, Akira S, (2003) Toll-like receptors. Annual Review of Immunology 21: 335-376.
13. Takeda K (2005) Toll-like Receptors and their Adaptors in Innate Immunity. Science: 3-11.
14. Nurieva R, Thomas S, Nguyen T, Martin-Orozco N, Wang Y, et al. (2006) T-cell tolerance or function is determined by combinatorial costimulatory signals. The EMBO Journal 25: 2623-2633.
15. Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL, et al. (2011) PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Molecular Medicine 3: 581-592.
16. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, et al. (2013) Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. New England Journal of Medicine 366: 2455-2465.
17. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. (2012) Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New England Journal of Medicine 366: 2443-2454.
18. Heissmeyer V, Macián F, Im S-H, Varma R, Feske S, et al. (2004) Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nature Immunology 5: 255-265.
19. Jeon M-S, Atfield A, Venuprasad K, Krawczyk C, Sarao R, et al. (2004) Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 21: 167-177.
20. Kojo S, Elly C, Harada Y, Langdon WY, Kronenberg M, et al. (2009) Mechanisms of NKT cell anergy induction involve Cbl-b-promoted monoubiquitination of CARMA1. Proceedings of the National Academy of Sciences of the United States of America 106: 17847-17851.
21. Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, et al. (2000) Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403: 216-220.
22. Paolino M, Thien CBF, Gruber T, Hinterleitner R, Baier G, et al. (2011) Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions. Journal of Immunology 186: 2138-2147.
23. Loeser S, Loser K, Bijker MS, Rangachari M, van der Burg SH, et al. (2007) Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. The Journal of Experimental Medicine 204: 879-891.
24. Bachmaier K, Krawczyk C, Kozieradzki I, Kong Y-Y, Sasaki T, et al. (2000) Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403: 211-216.
25. Krawczyk CM, Jones RG, Atfield A, Bachmaier K, Arya S, et al. (2005) Differential control of CD28-regulated in vivo immunity by the E3 ligase Cbl-b. The Journal of Immunology 174: 1472-1478.
26. Wohlfert EA, Callahan MK, Clark RB, (2004) Resistance to CD4+CD25+ regulatory T cells and TGF-β in Cbl-b-/- mice. Journal of Immunology 173: 1059-1065.
27. Wohlfert EA, Gorelik L, Mittler R, Flavell RA, Clark RB, (2006) Cutting Edge: Deficiency in the E3 Ubiquitin Ligase Cbl-b Results in a Multifunctional Defect in T Cell TGF-β Sensitivity in Vitro and In Vivo. Journal of Immunology 176: 1316-1320.
28. Lutz-Nicoladoni C, Wallner S, Stoitzner P, Pircher M, Gruber T, et al. (2011) Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine. Immunology and Cell Biology 2011: 1-5.
29. Purev E, Neff L, Horne WC, Baron R, (2009) c-Cbl and Cbl-b Act Redundantly to Protect Osteoclasts from Apoptosis and to Displace HDAC6 from β-Tubulin, Stabilizing Microtubules and Podosomes. Molecular Biology of the Cell 20: 4021-4030.
30. Huang F, Gu H, (2008) Negative regulation of lymphocyte development and function by the Cbl family of proteins. Immunological Reviews 224: 229-238.
31. Lutz MB, Kukutsch N, Ogilvie ALJ, Roßner S, Koch F, et al. (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. Journal of Immunological Methods 223: 77-92.
32. McLellan AD, (2002) Anatomic location and T-cell stimulatory functions of mouse dendritic cell subsets defined by CD4 and CD8 expression. Blood 99: 2084-2093.
33. Lyons AB, (2000) Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. Journal of Immunological Methods 243: 147-154.
34. Kamala T, (2007) Hock immunization: A humane alternative to mouse footpad injections. Journal Immunology Methods 328: 204-214.
35. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, et al. (2012) Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. The Journal of Immunology: 7516-7523.
36. Bauer B, Krumböck N, Ghaffari-Tabrizi N, Kampfer S, Villunger A, et al. (2000) T cell expressed PKCtheta demonstrates cell-type selective function. European Journal of Immunology 30: 3645-3654.
37. Morelli AE, (2001) Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood 98: 1512-1523.
38. Moser B, Loetscher P, (2001) Lymphocyte traffic control by chemokines. Nature Immunology 2: 123-128.
39. Roake JA, Rao AS, Morris PJ, Larsen CP, Hankins DF, et al. (1995) Dendritic Cell Loss from Nonlymphoid Tissues after Systemic Administration of Lipopolysaccharide, Tumor Necrosis Factor, and Interleukin 1. Journal of Experimental Medicien 181: 2237-2247.
40. Idzko M, Panther E, Stratz C, Müller T, Bayer H, et al. (2004) The serotoninergic receptors of human dendritic cells: identification and coupling to cytokine release. Journal of Immunology 172: 6011-6019.
41. O'Connell PJ, Wang X, Leon-Ponte M, Griffiths C, Pingle SC, et al. (2006) A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells. Blood 107: 1010-1017.
42. Medzhitov R, (2001) Toll-like receptors and innate immunity. Nature Reviews Immunology 1: 135-145.
43. Akira S, Takeda K, (2004) Toll-like receptor signalling. Nature Reviews Immunology 4: 499-511.
44. Curtsinger JM, Lins DC, Mescher MF, (2003) Signal 3 Determines Tolerance versus full Activation of naive CD8 T cells: Dissociating Proliferation and Development of Effector Function. The Journal of Experimental Medicine 197: 1141-1151.
45. Liechtenstein T, Dufait I, Lanna A, Breckpot K, Escors D, (2013) Modulating co-stimulation during antigen presentation to enhance cancer immunotherapy. Immunology' Endocrine & Metabolic Agents in Medicinal Chemistry 12: 1-23.
46. Heath WR, Carbone FR, (2001) Cross-presentation in viral immunity and self-tolerance. Nature Reviews Immunology 1: 126-134.
47. Burgdorf S, Lukacs-kornek V, Kurts C, (2012) The Mannose Receptor Mediates Uptake of Soluble but Not of Cell-Associated Antigen for Cross-Presentation. The Journal of Immunology 176: 6770-6776.
48. Sallusto F, Lanzavecchia A, (1994) Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor alpha. Journal of Experimental Medicine 179: 1109-1118.
49. Sallusto F, Cella M, Danieli C, Lanzavecchia A, (1995) Dendritic Cells Use Macropinocytosis and the Mannose Receptor to Concentrate Macromolecules in the Major Histocompatibility Complex Class II Compartment: Downregulation by Cytokines and Bacterial Products. Journal of Experimental Medicine 182: 389-400.
50. Wanping J, William JS, Christine H, Michael P, Asra M, et al. (1995) The receptor DEC205 expressed by DC and thymic epithelial cells is involved in antigen processing. Nature 375: 151-155.
51. Lanzavecchia A, (1990) Receptor-Mediated Antigen Uptake and its Effect on Antigen Presentation to Class II-Restricted T Lymphocytes. Annual Review of Immunology 8: 773-793.
52. Mukhopadhaya A, Hanafusa T, Jarchum I, Chen Y-G, Iwai Y, et al. (2008) Selective delivery of β cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Proceedings of the National Academy of Sciences of the United States of America 105: 6374-6379.
53. Mahnke K, Qian Y, Knop J, Enk AH, (2003) Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood 101: 4862-4869.
54. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, et al. (2002) Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance. Journal of Experimental Medicine 196: 1627-1638.
55. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, et al. (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. The Journal of Experimental Medicine 194: 769-779.
56. Ohl L, Mohaupt M, Czeloth N, Hintzen G, Kiafard Z, et al. (2004) CCR7 Governs Skin Dendritic Cell Migration under Inflammatory and Steady-State Conditions. Cell 21: 279-288.
57. Förster R, Schubel A, Breitfeld D, Kremmer E, Renner-Müller I, et al. (1999) CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99: 23-33.